Everest Med Reports Results from Trial of Antibiotic for MDR Infections

Everest Medicines, a China in-licensing company, reported positive top-line safety results from a China Phase I trial of taniborbactam in multi-drug resistant (MDR) pathogens.  Taniborbactam was tested in combination with cefepime. Everest acquired rights to cefepime-taniborbactam in Greater China and southeast Asia from VenatoRx of Pennsylvania. The two companies are conducting a pivotal Phase III trial of the cefepime-taniborbactam combination in patients with complicated urinary tract infection (cUTI). More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.